These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 32780846)

  • 21. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
    Zinzi A; Gaio M; Liguori V; Cagnotta C; Paolino D; Paolisso G; Castaldo G; Nicoletti GF; Rossi F; Capuano A; Rafaniello C
    Pharmacol Res; 2023 Apr; 190():106742. PubMed ID: 36963592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.
    Zhao H; Wang Y; Yin ETS; Zhao K; Hu Y; Huang H
    Front Med; 2020 Dec; 14(6):711-725. PubMed ID: 33259039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recognizing, defining, and managing CAR-T hematologic toxicities.
    Rejeski K; Subklewe M; Locke FL
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy.
    Hoyt R; Ye Z; Dasgupta A
    Clin Chim Acta; 2024 Jun; 559():119704. PubMed ID: 38697457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients.
    Sharma A; Singh V; Deol A
    Transplant Cell Ther; 2023 Feb; 29(2):108.e1-108.e7. PubMed ID: 36371048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties.
    Haidar G; Garner W; Hill JA
    Curr Opin Infect Dis; 2020 Dec; 33(6):449-457. PubMed ID: 33009139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Filgrastim associations with CAR T-cell therapy.
    Gaut D; Tang K; Sim MS; Duong T; Young P; Sasine J
    Int J Cancer; 2021 Mar; 148(5):1192-1196. PubMed ID: 33091961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
    Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
    Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
    Bouziana S; Bouzianas D
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
    Banerjee R; Marsal J; Huang CY; Lo M; Thiruvengadam SK; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
    Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
    Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
    Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
    Halford Z; Anderson MK; Bennett LL; Moody J
    Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.